Dr. R.E. Bruijn de

De heer de Bruijn is sinds 1 oktober 2018 verbonden aan Ziekenhuis Amstelland.

Aandachtsgebied

  • Oncologische urologie
  • Goedaardige prostaatvergroting
  • Niersteenlijden

Werkervaring

  • Fellow oncologische urologie, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
  • AIOS urologie, Amsterdam Universitair Medisch Centrum
  • AIOS urologie, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
  • AIOS urologie, Onze Lieve Vrouwen Gasthuis, Amsterdam
  • AIOS chirurgie (vooropleiding), Westfries Gasthuis, Hoorn
  • ANIOS urologie, Medisch Centrum Haaglanden, Den Haag
  • ANIOS heelkundige oncologische disciplines, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

Opleiding

  • Opleiding urologie, Cluster Amsterdam
  • Studie Geneeskunde, Universiteit van Amsterdam

BIG registratie
79913169401

Promotieonderzoek
Oktober 2020: Management and prognosis assessment in advanced renal cell carcinoma

Aanwezig
Maandag, dinsdag, donderdag en vrijdag. 

Publicaties
Deferred cytoreductive nephrectomy following presurgical VEGFR-targeted therapy in patients with primary metastatic clear-cell renal cell carcinoma: A pooled analysis of prospective trial data.

De Bruijn RE, Wimalasingham A, Stewart G, Blank C, Haanen JB, Klatte T, Staehler M, Powles T, Bex A
Eur Urol Oncol. 2020 Jan 16. pii: S2588-9311(20)30001-8 

Surgical safety of cytoreductive nephrectomy following sunitinib: Results from the multi-centre randomized controlled trial of immediate versus deferred nephrectomy (SURTIME).
De Bruijn RE, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, Van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Haanen JB, Bex A.
Eur Urol. 2019 Oct;76(4):437-440                                    

Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma.
Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BW, Wit EM, Bex A.
Scand J Urol. 2018 Oct - Dec;52(5-6):411-418 

An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors.
Kuusk T, Donswijk ML, Valdés Olmos RA, De Bruijn RE,Brouwer OR, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A.
EJNMMI Res. 2018 Dec 3;8(1):105  

External validation of a prediction model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L, de Bruijn RE, Van Werkhoven E, Beisland B, Heidenreich A Karam J, Kauffmann C, Klatte T, Ljungberg B, Staehler M, Stewart G, Uzzo R, Wood L, Wood C, Bex A.
World  J Urol. 2018 Dec;36(12):1973-1980 

Lymphatic drainage from renal tumors in vivo: a prospective sentinel node study using SPECT/CT imaging.
Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Grivas N, Hendricksen K, Horenblas S, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BWG, Wit EM, Bex A.

Author Reply: Observation after cytoreductive nephrectomy in patients with synchronous not completely resected metastases of renal cell carcinoma
De Bruijn RE, Bex A.
Urology. 2017 Nov;109:132-133                                     

Observation after cytoreductive nephrectomy in patients with synchronous not completely resected metastases of renal cell carcinoma.
De Bruijn RE, Kuusk T, Noe A, Blank C, Haanen JB, Horenblas S, Bex A.
Urology 2017 Nov; 109:127-133  

The current management of renal cell carcinoma.
Kuusk T, Grivas N, De Bruijn R, Bex A.
Minerva Med. 2017 Aug;108(4):357-369  

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.                   

Noe A, de Bruijn RE, Blank CU, Horenblas S, Haanen JB and BexA.                                                       

World J Urol. 2016 Aug;34(8):1067-72 

                                                                                   
Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.                                                                                   

De Bruijn RE, Nijkamp J, Noe A, Horenblas S, Haanen JB, Prevoo, W, Bex A.                                        

Urol Oncol. 2016 Jun;34(6):258.e7-258.e13 

 

Letter to the Editor: Timing of cholecystectomy in acute cholecystitis 

De Bruijn RE, Van IJsseldijk A and Sonneveld DJA 

Ann Surg. 2015 Aug;262(2):e87 

 

Case report. Urethroscopiegeassisteerde percutane lithotomie bij hypospadie.                                         

De Bruijn RE, Groenendijk PM, Berger CPAM and Leenarts JAF                                                    

Tijdschrift voor Urologie 2013: 3(8) 

 

Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation                                                                                                                      

Kroon BK, De Bruijn R, Prevoo W, Horenblas S and Bex A.                                                              

Urology 2013: 81(1) 

                                                                        

Premalignant cervical leasions in partners of patients with penile cancer: a cohort analysis.                     

De Bruijn RE, Heijdeman DAM, Kenter GG, Van Beurden M, van Tinteren H and Horenblas S.            

BJUI Int. 2013: 112(7) 

 

Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma?                                                                                                       

Bex A, Kroon BK and De Bruijn RE.                                                                                                              

J Surg Oncol; 2012:250479 

 

The haemostatic system in patients with type 2 diabetes with and without cardiovascular disease. 

Verkleij C, de Bruijn R, Meesters E, Gerdes V, Meijers J and Marx P.                                                             

Clin Appl Thromb Hemost. 2011;17(6)

 

 

Dr. R.E. Bruijn de